References:
1. Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, et al. Treatment Strategies for Deficiency of Adenosine Deaminase 2. N Engl J Med. 2019;3.
2. Elkan PN, Walsh T, Berkun Y, Hashkes PJ, Yalcinkaya F, Klevit RE, et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. N Engl J Med. 2014;11.
3. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. N Engl J Med. 2014;10.
4. Aksentijevich I, Moura NS, Barron K. Adenosine Deaminase 2 Deficiency. :23.
5. Montfrans JMV, Hartman EAR, Braun KPJ, Hennekam EAM, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. :9.
6. Uettwiller F, Sarrabay G, Rodero MP, Rice GI, Lagrue E, Marot Y, et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters. RMD Open. :6.
7. Meyts I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J Clin Immunol. :10.
8. Belot A, Wassmer E, Twilt M, Lega J-C, Zeef LA, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. 2014;7.
9. Sahin S. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency. Rheumatol Int. :8.
10. Alsultan A, Basher E, Mohammed R, Alfadhel M, Alqanatish J. Deficiency of ADA2 mimicking autoimmune lymphoproliferative syndrome in the absence of livedo reticularis and vasculitis. :4.
11. Ombrello A, Stone D, Hoffmann P, Jones A, Barham B, Barron K, et al. The deficiency of adenosine deaminase type 2-results of therapeutic intervention. :1.
12. Hashem H. Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2. :2.
13. Toplak N, Frenkel J, Ozen S, Lachmann HJ, Woo P, Koné-Paut I, et al. An International registry on Autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. :7.